Christopher E Brightling Selected Research

fevipiprant

1/2021	Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
1/2019	DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.
1/2016	Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher E Brightling Research Topics

Disease

96	Asthma (Bronchial Asthma) 10/2022 - 04/2002
47	Inflammation (Inflammations) 10/2022 - 12/2002
46	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 10/2003
9	Eosinophilia 01/2021 - 01/2005
9	Bronchitis 07/2019 - 05/2002
8	Airway Remodeling 01/2022 - 06/2012
8	Cough 01/2020 - 01/2003
6	Infections 01/2022 - 06/2011
6	Respiratory Hypersensitivity 11/2021 - 12/2002
6	Chronic Cough 01/2020 - 01/2004
5	Bacterial Infections (Bacterial Infection) 07/2021 - 06/2011
4	Symptom Flare Up 01/2022 - 01/2022
4	COVID-19 01/2022 - 07/2021
3	Wounds and Injuries (Trauma) 01/2021 - 06/2012
2	Emphysema 01/2021 - 01/2020
2	Rhinosinusitis 01/2021 - 07/2019
2	Airway Obstruction (Choking) 12/2019 - 06/2012
2	Pneumonia (Pneumonitis) 09/2015 - 06/2011
1	Virus Diseases (Viral Diseases) 03/2022

Drug/Important Bio-Agent (IBA)

39	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2003
34	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2005
11	CytokinesIBA 03/2022 - 12/2002
10	Bronchodilator Agents (Bronchodilators)IBA 01/2021 - 02/2006
9	Monoclonal AntibodiesIBA 01/2022 - 01/2018
9	Interleukin-13IBA 01/2021 - 11/2004
8	16S Ribosomal RNAIBA 01/2021 - 04/2016
6	mepolizumabIBA 10/2021 - 03/2009
6	SteroidsIBA 01/2021 - 01/2012
5	Interleukin-33IBA 01/2022 - 09/2015
5	InterleukinsIBA 10/2021 - 09/2015
5	Proteins (Proteins, Gene)FDA Link 12/2020 - 07/2010
5	Immunoglobulin E (IgE)IBA 01/2020 - 12/2010
5	Pharmaceutical PreparationsIBA 01/2018 - 03/2004
4	tralokinumabIBA 10/2022 - 09/2015
4	Formoterol Fumarate (Oxis)FDA Link 01/2022 - 01/2022
4	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 01/2022 - 01/2022
4	Muscarinic AntagonistsIBA 01/2022 - 01/2022
4	Azithromycin (Zithromax)FDA LinkGeneric 01/2022 - 01/2022
4	AllergensIBA 01/2022 - 06/2012
4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 06/2011
4	C-Reactive ProteinIBA 10/2021 - 06/2011
4	Biological ProductsIBA 10/2021 - 09/2011
4	benralizumabIBA 01/2021 - 11/2014
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 01/2005
4	ChemokinesIBA 01/2020 - 05/2005
3	Interleukin-6 (Interleukin 6)IBA 03/2022 - 07/2021
3	SmokeIBA 01/2022 - 08/2015
3	tezepelumabIBA 01/2022 - 01/2021
3	Immunoglobulin G (IgG)IBA 01/2022 - 12/2010
3	prostaglandin D2 receptorIBA 01/2021 - 01/2016
3	fevipiprantIBA 01/2021 - 01/2016
3	LigandsIBA 04/2016 - 05/2005
3	Prednisolone (Predate)FDA LinkGeneric 01/2016 - 07/2010
3	Chemokine ReceptorsIBA 12/2006 - 12/2002
2	AntioxidantsIBA 01/2022 - 01/2018
2	astegolimabIBA 01/2022 - 01/2021
2	OvalbuminIBA 01/2022 - 01/2016
2	Mannitol (Osmitrol)FDA LinkGeneric 11/2021 - 11/2008
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2021 - 10/2006
2	Interleukin-5 (Interleukin 5)IBA 10/2021 - 01/2021
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 10/2021 - 01/2018
2	Volatile Organic CompoundsIBA 07/2021 - 01/2019
2	AlarminsIBA 01/2021 - 09/2015
2	RNA (Ribonucleic Acid)IBA 01/2021 - 12/2020
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 11/2010
2	CalciumIBA 01/2021 - 12/2020
2	Butyrates (Butyrate)IBA 11/2020 - 01/2020
2	GoldIBA 01/2020 - 01/2016
2	Protein Isoforms (Isoforms)IBA 01/2020 - 08/2015
2	Prostaglandin D2IBA 01/2020 - 01/2004
2	Messenger RNA (mRNA)IBA 01/2020 - 01/2019
2	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 12/2019 - 01/2019
2	PeriostinIBA 01/2018 - 09/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 07/2012
2	GlucocorticoidsIBA 01/2017 - 01/2015
2	Urokinase Plasminogen Activator ReceptorsIBA 08/2015 - 06/2012
2	Histones (Histone)IBA 05/2015 - 07/2012
2	Phenobarbital (Luminal)FDA Link 02/2013 - 06/2012
2	GTP-Binding Proteins (G-Protein)IBA 06/2012 - 01/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010 - 02/2006
2	Methacholine Chloride (Methacholine)FDA Link 02/2006 - 04/2002
1	Type II Tumor Necrosis Factor ReceptorsIBA 03/2022
1	Interleukin-8 (Interleukin 8)IBA 03/2022
1	trimethyloxamine (trimethylamine N-oxide)IBA 01/2022
1	Air Pollutants (Pollutants, Air)IBA 01/2022
1	Acetylcarnitine (Alcar)IBA 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	CollagenIBA 01/2022
1	Choline (Choline Chloride)IBA 01/2022
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2022
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022
1	trimethylamineIBA 01/2022
1	Betaine (C.B.B.)FDA Link 01/2022
1	Clostridium perfringens epsilon-toxinIBA 11/2021
1	GadoliniumIBA 11/2021

Therapy/Procedure

41	Therapeutics 01/2022 - 01/2003
8	Biological Therapy 01/2022 - 01/2020
4	Bronchial Thermoplasty 11/2019 - 01/2014
3	Precision Medicine 01/2020 - 11/2016
1	Ambulatory Care (Outpatient Care) 03/2022